CEO Provides First Half 2017 General Corporate Update

CEO Provides First Half 2017 General Corporate Update

Ziona, Israel - June 28, 2017 -

Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine candidate M-001, today provided a

general corporate update of its activities in the first half of 2017.

Babecoff, BiondVax CEO, commented, "The first half of 2017 was exciting and important for BiondVax. Three major events

occurred: (1) We welcomed a major strategic investor, Marius Nacht and his aMoon Fund, who currently hold approximately

20% of our company; (2) Israel's Ministry of Economy approved a grant covering 20% of the construction costs of a commercial

scale manufacturing facility; and also significantly advancing our goals, (3) the European Investment Bank (EIB) signed a

20 million non-dilutive funding agreement to support commercial production and Phase 3 trials. I am thrilled that

we now have the resources to launch our Phase 3 program towards commercialization."

million in non-dilutive funding

Patent Allowed in Canada

Phase 2b Trial Progress and Results Timetable

1 The research has received

funding from the European Union Seventh Framework Program (FP7/2007-2013) under grant agreement n 602012.

Mid-Size Manufacturing Facility

Investment by Leading Investor

BiondVax Pharmaceuticals Ltd

is a clinical phase biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season

protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes

a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system

for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. Please visit www.biondvax.com.

further information, please contact:

2 http://www.biondvax.com/2016/11/biondvax-phase-2b-trial-preliminary-safety-results-the-universal-flu-vaccine-candidate-is-safe-and-well-tolerated/

Forward Looking Statements

press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such

as "expect," "believe," "intend," "plan," "continue," "may,"

"will," "anticipate," and similar expressions are intended to identify forward-looking statements. These

forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to

certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results

to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but

are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome, the results

of the Phase 2 & 3 trials, delays or obstacles in launching and/or successfully completing

our clinical trials, the receipt and timing of approved grant funds, our ability

to procure the funds and permits and other governmental authorization for a commercial size manufacturing plant, our ability to

satisfy rigorous regulatory requirements, the impact of the global economic environment on the Company customer target

base, the adequacy of available cash resource and the ability to raise capital when needed. More

detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors"

in our Annual Report on Form 20-F for the year ended December 31, 2016 filed with the U.S. Securities and Exchange Commission,

or SEC, which is available on the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC and

the Tel-Aviv Stock Exchange.